| 新型抗凝药物防治静脉血栓栓塞症的研究进展 |
| |
| 引用本文： | 白媛,胡晓芸.新型抗凝药物防治静脉血栓栓塞症的研究进展[J].国际呼吸杂志,2016(15):1197-1200. |
| |
| 作者姓名： | 白媛 胡晓芸 |
| |
| 作者单位： | 山西医科大学第一医院呼吸内科, 太原,030001 |
| |
| 摘 要： | 静脉血栓栓塞症(VTE)是由多种遗传性和获得性危险因素共同作用的结果,抗凝治疗是预防和治疗VTE的基础.传统抗凝药物如低分子肝素和华法林防治VTE的有效性已被临床实践充分证实,但其缺点也不容忽视.近年来新型抗凝药物如利伐沙班、阿哌沙班和达比加群等在预防和治疗VTE领域进行了大量临床研究,其安全性与有效性均得到证实,为临床医师治疗VTE提供了更多的选择.
|
| 关 键 词： | 新型抗凝药物 利伐沙班 阿哌沙班 达比加群 静脉血栓栓塞症 |
Advances of new anticoagulant drugs in prevention and treatment of venous thromboembolism |
| |
| Abstract: | Venous thromboembolism (VTE) is a result of a variety of genetic and acquired risk factors.Anticoagulant therapy is the basis for the prevention and treatment of VTE.Effectiveness of traditional anticoagulant drugs such as low molecular weight heparin and warfarin for the prevention and treatment of VTE has been fully confirmed by clinical practice,but their shortcomings also can not be ignored.In recent years,a large amount of clinical researches of new anticoagulant drugs such as rivaroxaban,apixaban and dabigatran have been done in the field of prevention and treatment of VTE.The safety and effectiveness of new anticoagulant drugs also have been confirmed,which provides more choices for clinician. |
| |
| Keywords: | New anticoagulant drugs Rivaroxaban Apixaban Dabigatran Venous thromboembolism |
| 本文献已被 万方数据 等数据库收录！ |
|
